Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 03:14:24 +0200Fri, 12 Jul 2024 15:38:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, Tirzepatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0285/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002360-pip02-22-m01Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, Tirzepatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0285/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002360-pip02-22-m01Fri, 12 Jul 2024 15:38:00 +0200Human medicineMounjaro : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5620-en_3.pdfMounjaro : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5620-en_3.pdfFri, 05 Jul 2024 13:40:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/mounjaroHuman medicines European public assessment report (EPAR): Mounjaro, tirzepatide, Date of authorisation: 15/09/2022, Revision: 8, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/mounjaroFri, 05 Jul 2024 10:51:00 +0200Human medicine